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Abstract
Objective: This study analyzes the clinical and laboratory findings of children with primary hemophagocytic 
lymphohistiocytosis (HLH) followed in various referral centers of Turkey.
Materials and Methods: A simple three-page questionnaire prepared by the Turkish Histiocyte Study Group 
was used for documentation of patient data.
Results: Age at diagnosis varied from 0.6 to 78 months (median±SD, 16.5±26.1). Sex distribution was 
almost equal (F/M=10/12). The frequencies of parental consanguinity and sibling death in the family his-
tory were 100% and 81.1%, respectively. The most common clinical findings were hepatomegaly (100%) 
and fever (95%). The most common laboratory findings were anemia (100%), hyperferritinemia (100%) and 
thrombocytopenia (90.9%). Triglyceride and total bilirubin levels in the deceased versus surviving group 
appear to be high (triglyceride: 394±183 mg/dl, 289±7 mg/dl; total bilirubin: 2.7±6.9 mg/dl, 0.5±1.2 mg/
dl, respectively).Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a 
hyperinflammation disorder characterized by fever, 
splenomegaly, bicytopenia, hypertriglyceridemia 
and/or hypofibrinogenemia, hyperferritinemia, ele-
vated soluble CD25 levels, decreased or absent 
natural killer cell activity, and hemophagocytosis in 
the bone marrow, spleen, lymph nodes or other tis-
sues [1]. Primary or familial hemophagocytic lym-
phohistiocytosis (FHLH) is an autosomal recessive 
disorder of immune dysfunction caused by muta-
tions in Perforin, Munc13-4, Syntaxin 11 and STBX2 
genes [2-5]. Secondary HLH develops in some dis-
orders such as infections, toxins, malignancies, and 
autoimmune or immune deficiency disorders [6].
Males and females are affected at equal frequen-
cies. Onset of FHLH occurs generally in infancy, but 
rarely, patients can be symptomatic at later ages, 
even in adulthood [7]. The main pathogenetic 
mechanism is defective natural killer cell function 
and uncontrolled T cell activation leading to 
increased levels of cytokines such as interferon-a 
(IFN-a), tumor necrosis factor-_ (TNF-_), interleu-
kin-1 (IL-1), IL-6, IL-10, and soluble IL-2 receptor [8]. 
Profound hypercytokinemia activates macrophages, 
and hemophagocytosis ensues. Infiltration of bone 
marrow, liver, spleen, and the central nervous sys-
tem (CNS) with macrophages and T lymphocytes 
results in multiorgan dysfunction with high mortali-
ty. Prognosis is poor for FHLH patients treated with 
chemotherapy alone, with an estimated five-year 
survival (SE) below 20% [9].
Allogenic hematopoietic stem cell transplantation 
(HSCT) is the only accepted curative therapy [1,6]. 
In this study, we report the clinical and laboratory 
data of 22 children with HLH who were followed in 
different pediatric referral centers in Turkey over the 
past 10 years, together with a comprehensive review 
of this rare disorder. 
Materials and Methods
This study retrospectively analyzed the data of 22 
children with HLH who were diagnosed and fol-
lowed-up in 13 pediatric referral centers in Turkey. 
A simple three-page questionnaire was sent to each 
center by the Turkish Histiocyte Study Group to stan-
dardize data collection. This study has local ethical 
committee approval.
All children were diagnosed as HLH between 
January 1995 to June 2005 according to Diagnostic 
Guidelines for HLH 1994 and 2004. Patients with 
parental consanguinity and history of sibling death 
were accepted as having FHLH. Parental consan-
guinity was present in all of the patients and history 
Conclusion: We concluded that fever, hepatosplenomegaly, anemia, thrombocytopenia, and hyperferri-
tinemia are the most common clinical and laboratory findings in primary HLH. Increased triglyceride and 
total bilirubin level at the time of diagnosis might be an indicator of poor prognosis in HLH.
(Turk J Hematol 2010; 27: 157-62)
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Özet
Amaç: Primer hemofagositik lenfohistiositoz tan×s× ile Türkiye’deki farkl× merkezlerde takip edilen 
hastalar×n klinik ve laboratuar deùerlerini deùerlendirmektir.
Yöntem ve Gereçler: Hasta verilerinin deùerlendirilmesi için Türk Histiosit Çal×üma Grubu taraf×ndan 
düzenlenmiü 3 sayfal×k soru formu kullan×ld×. 
Bulgular: Olgular×n tan× s×ras×ndaki yaülar× 0.6 ile 78 ay aras×nda idi (median±SD, 16.5±26.1). Cinsiyet 
daù×l×m× eüite yak×nd× (K/E=10/12). Anne-baba akrabal×ù× ve kardeü ölüm öyküsü oranlar× s×ras× ile %100 
ve %81.1 idi. Ens×k görülen klinik bulgular hepatomegali (%100), ateü (%95), labaratuvar bulgular× ise 
anemi (%100), hiperferritinemi (%100) ve trombositopeniydi (%90.9). Ölen olgular×n trigliserid ve bili-
rubin düzeyleri yüksek gibi gözükmekteydi (trigliserid; 394±183 mg/dL, 289±7 mg/dL, total bilirubin; 
2.7±6.9 mg/dL, 0.5±1.2 mg/dL)
Sonuç: Ateü, hepatosplenomegali, anemi, hiperferritinemi ve trombositopeni primer HLH'li hastalarda en 
s×k görülen klinik ve labaratuvar bulgulard×r. Tan× s×ras×ndaki artm×ü trigliserid ve bilirubin düzeyleri kötü 
prognostik belirteç olabilir. (Turk J Hematol 2010; 27: 157-62)
Anahtar kelimeler: Primer hemofagositik lenfohistiositozis, klinik ve laboratuvar veriler
Geliü tarihi: 7 Haziran 2009    Kabul tarihi: 11 May×s 2010
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Primary HLH in Turkey Turk J Hematol 2010; 27: 157-62 258of sibling death in 18 of them. All patients fulfilled at 
least five cardinal criteria of HLH at the time of diag-
nosis, including fever, hepatosplenomegaly, bicyto-
penia and/or pancytopenia, hypertriglyceridemia 
and/or hypofibrinogenemia, hyperferritinemia, and 
hemophagocytosis in the bone marrow, liver or 
lymph nodes [10]. They had no evidence of malig-
nancy, infection, metabolic disease, or any other 
disorder that might have been the cause of present-
ing symptoms and hemophagocytosis. Patients 
were evaluated regarding age, clinical findings, 
laboratory data, treatment, and prognosis, using 
descriptive statistics. A molecular genetic study 
could be performed in only 4 patients.
Results
The age of the patients ranged from 0.6 to 78 
months at the time of diagnosis. Sex distribution 
was almost equal (F/M=10/12). Initial clinical find-
ings are shown in Tables 1 and 2. Rates of parental 
consanguinity and sibling death were 100% (22/22) 
and 81.1% (18/22), respectively. The patients were 
diagnosed by bone marrow aspiration in 19 (86.4%) 
and biopsy from the liver in 2 (9%), spleen in 1 
(4.5%) and lymph nodes in 1 (4.5%). 
Hepatomegaly was present in all the patients, 
and 95.5% (21/22) had fever and splenomegaly. The 
most common laboratory findings were anemia 
(100%), hyperferritinemia (100%) and thrombocyto-
penia 90.9% (20/22). Other findings are shown in 
Tables 1 and 2.
Cerebromeningeal symptoms including seizures 
or cerebral nerve palsies occurred in 27.3% (6/22) of 
the patients in our study group. Fourteen (63.3%) 
children received supportive treatment (fresh fro-
zen plasma and erythrocyte concentrates) and cor-
ticosteroid, intravenous immunoglobulin (IVIG), 
and vincristine therapy. HLH-94 and HLH-2004 treat-
ment protocols were given in 4 (18.8%) and 3 
(13.6%) children, respectively. One child had under-
gone bone marrow transplantation, and she died 
with chronic graft-versus-host disease and pulmo-
nary hypertension. Eighteen (86.3%) patients died 
due to progressive disease, infection and bleeding. 
Three children were alive at the time of preparation 
of the article.
Discussion
Familial hemophagocytic lymphohistiocytosis 
(FHLH) is a rare autosomal recessive disease char-
acterized by fever, hepatosplenomegaly, cytopenia, 
Table 2. Laboratory findings of patients with hemophagocytic lym-
phohistiocytosis at diagnosis
Number of patients (n) 
n=22  
Laboratory Findings  mean±SD  range
  Hb (g/dl)  6.85±1.6  3.6 8 9.8
 Platelet  (x109/L)  42±157  2 - 752
 ANC  (/mm3)  895± 5632  50 - 24000
  AST (U/L)  132±302  21 - 1176
  ALT (U/L)  102± 1171  22 - 5446
  Triglyceride (mg/dl)  374±179  284 - 999
  LDH (U/L)  930±968  106 - 3547
  Ferritin (mg/dl)   1434±1485   576 - 5654 
  Serum sodium (mEq/L)  133±5.7  124 - 148
  T. Bilirubin (mg/dl)  2±6.5  0.4 - 22
  PT (sec)  14±18  2 - 90
  APTT (sec)   39±32  27 - 180
  Fibrinogen (g/L)  1.28± 1.38  0 - 4.2
Hb: Hemoglobin: ANC: Absolute neutrophil count; AST: Aspartate aminotransfer-
ase; ALT: Alanine aminotransferase; LDH: Lactic acid dehydrogenase; T. bilirubin: 
Total bilirubin; PT: Prothrombin time; APTT: Activated partial thromboplastin time
Table 1. Clinical findings of patients with hemophagocytic lympho-
histiocytosis at diagnosis
n=22 Number  %
Gender  
 Girl    10  45.5
 Boy  12  54.5
Age (months)  16.5  0.6 - 78 
   (median)    (range)
Positive History    
 Consanguinity  22  100
 Fever    21  95.5
 Sibling  death  18  81.8
  Skin eruptions   5  22.7
Clinical Findings   
 Hepatomegaly  22  100
 Splenomegaly  21  95.5
 Fever  21  95.5
  Lymphadenomegaly*    7  31.8
 Cerebromeningeal  symptoms  6  27.3
 Bleeding**  4  18.2
 Skin  eruptions  4  18.2
*Cervical, occipital, inguinal, **Gingival, epistaxis
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other tissues [1]. It is known to occur frequently in 
children under 2 years of age [6,10]. Due to the very 
high rate of consanguineous marriages (21%) in 
Turkey, the expected incidence of HLH should be 
high as well. Many reports on FHLH in Turkish 
patients justify this conclusion [11-13]. Although 
there are no nationwide epidemiologic data, in one 
study, the frequency of the HLH among hospitalized 
patients was found to be 7.5/10000, and the rate of 
consanguineous marriage was reported as 68% in 
HLH patients [14]. This was 100% in our study 
group, and 81.8% had family history of a sibling 
death. 
In this report, we analyzed the data of 22 patients 
with HLH who were diagnosed and treated in differ-
ent pediatric referral centers between January 1995 
and 2005. Along with the high frequency of consan-
guineous marriages in the study group, each patient 
fulfilled at least five cardinal criteria of HLH. Although 
molecular genetic study is now available in a center 
in Turkey (Hacettepe University, Ankara), it could 
only be performed in a very limited number of 
patients. Despite this limitation, we considered that 
it would be informative to document the available 
clinical and laboratory data of these children with 
HLH from Turkey, where it is encountered relatively 
more frequently than in other parts of the world. 
The clinical findings of HLH are generally non-
specific, and the most common symptoms are 
known to be fever and hepatosplenomegaly. Many 
patients with HLH present with mild to moderate 
signs of infection, which delays the diagnosis.
Consistent with previous studies, the most com-
mon initial findings in our patients were hepato-
megaly, splenomegaly and fever. There was only 1 
patient who was afebrile at the time of diagnosis. 
Although fever is a very common finding in HLH, it 
may not occur in a small number of patients for 
unknown reasons. Some patients might develop 
fever during follow-up, as in our patient. Clinicians 
should be aware of this possibility in the diagnosis 
of HLH. The most common laboratory findings 
were anemia, hyperferritinemia and thrombocyto-
penia, as expected. This may be due to undetect-
able infections, or the patients may have acquired 
HLH. Although platelet and absolute neutrophil 
counts were normal in 2 patients in the initial peri-
od, these patients had cytopenia in more than 2 of 3 
lineages and fulfilled the criteria of HLH. As is 
known, the presence of infection does not discrimi-
nate FHLH from the acquired form. FHLH episodes 
are triggered by infectious agents [6]. 
Hemophagocytosis in the bone marrow or retic-
uloendothelial system including liver, spleen and 
lymph nodes was reported to be detected in one-
half or two-thirds of the patients with HLH, so 
hemophagocytosis may not always be observed in 
the bone marrow aspiration, especially at the dis-
ease onset. When the diagnosis of HLH is strongly 
suspected, clinicians should make a thorough 
microscopic examination of the bone marrow aspi-
ration smear or serial repeated aspirations should 
be done. In our series, we observed hemophagocy-
tosis in all of the patients in the microscopic exami-
nation, and it seems to be the highest ratio of deter-
mining hemophagocytosis in HLH when compared 
with previous reports in the literature.
Although elevated lactate dehydrogenase (LDH) 
is emphasized as a supporting criterion by some 
authors, it is not accepted as a diagnostic laboratory 
criterion for diagnosis of HLH [10]. In our group, 19 
of 22 (86.7%) patients had elevated LDH level. It is 
notable that in our study group, the frequency of 
elevated LDH was remarkably high. 
On the other hand, cerebromeningeal symptoms 
including seizures or cerebral nerve palsies occurred 
in 27.3% (6/22) of the patients in our study group. 
This figure is slightly less than those reported in pre-
vious studies [13-16].
There is limited data regarding the association 
between the prognosis of disease and triglyceride 
metabolism. Monitoring the triglyceride level is a 
recently defined follow-up parameter in the evalua-
tion of treatment response in secondary HLH as 
reported by Okamoto et al. [17]. Sarper et al. [18] 
reported low triglyceride levels in 2 patients diag-
nosed with HLH. 
In addition to perforin, the Munc13-4, syntaxin 11, 
and recently Munc18-2 mutations are described 
[2-5]. A molecular genetic study was performed in 
only 4 patients, and syntaxin mutation was detected 
in 1 of them [19]. 
We cannot discuss event-free survival because 
of data from heterogeneous hospital records and 
the differences between the therapy regimens of 
the centers. Seven of the 22 children received spe-
cific therapy for HLH and only 1 of them survived, 
F×üg×n et al.
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(etoposide), IVIG and steroids survived. All surviv-
ing patients had a history of parental consanguinity 
and 2 of them had sibling death.
Etoposide, dexamethasone, cyclosporine A, and 
intrathecal methotrexate have been the mainstay of 
all HLH treatment protocols because of their differ-
ent properties. One of the basic findings of HLH at 
the cellular level is decreased apoptosis, and etopo-
side has a more significant proapoptotic effect. Use 
of these medications at different dosages and dura-
tions in 2 of our surviving patients might explain the 
favorable outcome. The genetic analysis of these 
patients will further clarify our results. 
The prognosis of patients with HLH who require 
admission to any center has been regarded as 
extremely poor. SCT is the only curative treatment 
option for patients with HLH [1,6]. There are two 
major problems before bone marrow transplanta-
tion: finding a matched sibling donor and keeping 
the patients alive until the transplantation [1]. 
Without a bone marrow transplant, the child is 
always at risk of a severe or fatal activation and will 
have difficulty surviving beyond their first birthday. 
Unfortunately, only 1 patient underwent peripheral 
SCT from a fully matched mother in the study peri-
od, and she died because of chronic graft-versus-
host disease and pulmonary hypertension. 
In conclusion, fever, hepatosplenomegaly, ane-
mia, thrombocytopenia, and hyperferritinemia are 
the most common clinical and laboratory findings 
in primary HLH. Parental consanguinity and pres-
ence of affected siblings seem to be an important 
clue for diagnosis. Increased triglyceride and total 
bilirubin levels at the time of diagnosis might be 
poor prognostic indicators in HLH, but this requires 
further investigation.
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